UNSPSC 51332870: Promazine hydrochloride

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H20N2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U16EOR79U4, chemically known as 10h-phenothiazine-10-propanamine, n,n-dimethyl-, monohydrochloride but more generally known as promazine hydrochloride, which bears US NIH Compound Identifier 4926. European Medicines Agency schedules Promazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04067MIG.

UNSPSC 51332870 Promazine hydrochloride is a Commodity code that in practice encompasses pharmaceutical products and drug-related systems procured by state and local health authorities, though recent activity shows minimal direct solicitation for promazine itself. Instead, state and local governments are actively buying naloxone, safe drug deactivation systems, and generic multi-source pharmaceuticals through cooperative purchasing vehicles and competitive solicitations. The issuing bodies span county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida and the Texas Health and Human Services Commission represent the primary recent buyers, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) establishing statewide and multi-state contracts for pharmaceutical distribution. Work ranges from direct procurement of emergency-response medications (naloxone paired with drug deactivation systems) to exploratory contracting for direct-to-manufacturer prescription fulfillment and broad-based generic pharmaceutical supply agreements through authorized wholesalers.

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, closing July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs, signaling future formal procurement intent. MMCAP released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and awards effective July 1, 2026. All three opportunities required fixed pricing, compliance with cGMP and FDA standards, E-Verify or equivalent authorization verification, and submission of detailed product specifications including NDC codes. The cooperative purchasing structure and multistate scope in the MMCAP solicitation indicate sustained demand for pharmaceutical supply aggregation across multiple jurisdictions.